相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
Philip A. Philip et al.
CANCER (2012)
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Farbod Shojaei
CANCER LETTERS (2012)
Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial
A. O. Kaseb et al.
ONCOLOGY (2012)
Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications
Catherine Frenette et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Phase 2 Trial of Bevacizumab, Capecitabine, and Oxaliplatin in Treatment of Advanced Hepatocellular Carcinoma
Weijing Sun et al.
CANCER (2011)
Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia
Kwang-Hyub Han et al.
ONCOLOGY (2011)
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
C-H Hsu et al.
BRITISH JOURNAL OF CANCER (2010)
Bevacizumab toxicities and their management in ovarian cancer
Leslie M. Randall et al.
GYNECOLOGIC ONCOLOGY (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Current approach in the treatment of hepatocellular carcinoma
Luigi Rossi et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2010)
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
E. D. Saad et al.
ANNALS OF ONCOLOGY (2009)
Acute and long-term gastrointestinal consequences of chemotherapy
Frederic Di Fiore et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2009)
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Abby B. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Melanie B. Thomas et al.
CANCER (2007)
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
AX Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
W Yeo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
PA Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
International trends and patterns of primary liver cancer
KA McGlynn et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
分享论文
